1.24 0.1 (8.77%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 1.53 | 1-year : | 1.74 |
Resists | First : | 1.31 | Second : | 1.49 |
Pivot price | 1.14 ![]() |
|||
Supports | First : | 1.03 | Second : | 0.86 |
MAs | MA(5) : | 1.15 ![]() |
MA(20) : | 1.12 ![]() |
MA(100) : | 1.28 ![]() |
MA(250) : | 2.09 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 28.8 ![]() |
D(3) : | 23.8 ![]() |
RSI | RSI(14): 59.4 ![]() |
|||
52-week | High : | 9.37 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SXTC ] has closed below upper band by 14.3%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.28 - 1.29 | 1.29 - 1.3 |
Low: | 1.14 - 1.15 | 1.15 - 1.16 |
Close: | 1.23 - 1.24 | 1.24 - 1.25 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Thu, 25 Jul 2024
Did China SXT Pharmaceuticals Inc (SXTC) perform well in the last session? - US Post News
Wed, 24 Jul 2024
Balance Sheet Insights: China SXT Pharmaceuticals Inc (SXTC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Thu, 04 Jul 2024
Market Watch Highlights: China SXT Pharmaceuticals Inc (SXTC) Ends on an Downturn Note at 1.06 - The Dwinnex
Wed, 17 Apr 2024
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Thu, 26 Oct 2023
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule - Yahoo Finance
Thu, 05 Oct 2023
China SXT Pharma (NASDAQ: SXTC) to jump 2,500% - a purely technical move - Dhaka Tribune
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 1 (M) |
Shares Float | 1 (M) |
Held by Insiders | 25 (%) |
Held by Institutions | 0.5 (%) |
Shares Short | 37 (K) |
Shares Short P.Month | 35 (K) |
EPS | -26.96 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.96 |
Profit Margin | 0 % |
Operating Margin | -995.1 % |
Return on Assets (ttm) | -45.8 % |
Return on Equity (ttm) | -141.7 % |
Qtrly Rev. Growth | -22.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 1.86 |
EBITDA (p.s.) | -14.47 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.05 |
PEG Ratio | 0 |
Price to Book value | 0.17 |
Price to Sales | 0.66 |
Price to Cash Flow | -10.19 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |